Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial
Introduction Atrial fibrillation is the most common heart arrhythmia with a prevalence of approximately 2% in the western world. Atrial fibrillation is associated with an increased risk of death and morbidity. In many patients, a rate control strategy is recommended. The optimal heart rate target is...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-03-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/11/3/e044744.full |
id |
doaj-44808c24001644fd9b94d34f39f20a12 |
---|---|
record_format |
Article |
spelling |
doaj-44808c24001644fd9b94d34f39f20a122021-07-02T13:12:12ZengBMJ Publishing GroupBMJ Open2044-60552021-03-0111310.1136/bmjopen-2020-044744Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trialChristian Gluud0Emil Eik Nielsen1Joshua Buron Feinberg2Michael Hecht Olsen3Axel Brandes4llan Raymond5Walter Bjørn Nielsen6Frank Stensgaard-Hansen7Ulrik Dixen8Ole Dyg Pedersen9Uffe Jakob Ortved Gang10Department of Regional Health Research, University of Southern Denmark Faculty of Health Sciences, Odense, DenmarkDepartment of Internal Medicine – Cardiology Section, Holbaek Hospital, Holbaek, Region Zealand, DenmarkDepartment of Internal Medicine – Cardiology Section, Holbaek Hospital, Holbaek, Region Zealand, DenmarkDepartment of Internal Medicine – Cardiology Section, Holbaek Hospital, Holbaek, Region Zealand, DenmarkDepartment of Cardiology, Odense University Hospital, Odense C, DenmarkDepartment of Internal Medicine – Cardiology Section, Holbaek Hospital, Holbaek, Region Zealand, DenmarkDepartment of Internal Medicine – Cardiology Section, Holbaek Hospital, Holbaek, Region Zealand, DenmarkDepartment of Internal Medicine – Cardiology Section, Holbaek Hospital, Holbaek, Region Zealand, DenmarkDepartment of Cardiology, Hvidovre University Hospital, Hvidovre, DenmarkDepartment of cardiology, Zealand University Hospital Roskilde, Roskilde, Region Zealand, DenmarkDepartment of cardiology, Zealand University Hospital Roskilde, Roskilde, Region Zealand, DenmarkIntroduction Atrial fibrillation is the most common heart arrhythmia with a prevalence of approximately 2% in the western world. Atrial fibrillation is associated with an increased risk of death and morbidity. In many patients, a rate control strategy is recommended. The optimal heart rate target is disputed despite the results of the the RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient vs strict rate control II (RACE II) trial.Our primary objective will be to investigate the effect of lenient rate control strategy (<110 beats per minute (bpm) at rest) compared with strict rate control strategy (<80 bpm at rest) on quality of life in patients with persistent or permanent atrial fibrillation.Methods and analysis We plan a two-group, superiority randomised clinical trial. 350 outpatients with persistent or permanent atrial fibrillation will be recruited from four hospitals, across three regions in Denmark. Participants will be randomised 1:1 to a lenient medical rate control strategy (<110 bpm at rest) or a strict medical rate control strategy (<80 bpm at rest). The recruitment phase is planned to be 2 years with 3 years of follow-up. Recruitment is expected to start in January 2021. The primary outcome will be quality of life using the Short Form-36 (SF-36) questionnaire (physical component score). Secondary outcomes will be days alive outside hospital, symptom control using the Atrial Fibrillation Effect on Quality of Life, quality of life using the SF-36 questionnaire (mental component score) and serious adverse events. The primary assessment time point for all outcomes will be 1 year after randomisation.Ethics and dissemination Ethics approval was obtained through the ethics committee in Region Zealand. The design and findings will be published in peer-reviewed journals as well as be made available on ClinicalTrials.gov.Trial registration number NCT04542785.https://bmjopen.bmj.com/content/11/3/e044744.full |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christian Gluud Emil Eik Nielsen Joshua Buron Feinberg Michael Hecht Olsen Axel Brandes llan Raymond Walter Bjørn Nielsen Frank Stensgaard-Hansen Ulrik Dixen Ole Dyg Pedersen Uffe Jakob Ortved Gang |
spellingShingle |
Christian Gluud Emil Eik Nielsen Joshua Buron Feinberg Michael Hecht Olsen Axel Brandes llan Raymond Walter Bjørn Nielsen Frank Stensgaard-Hansen Ulrik Dixen Ole Dyg Pedersen Uffe Jakob Ortved Gang Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial BMJ Open |
author_facet |
Christian Gluud Emil Eik Nielsen Joshua Buron Feinberg Michael Hecht Olsen Axel Brandes llan Raymond Walter Bjørn Nielsen Frank Stensgaard-Hansen Ulrik Dixen Ole Dyg Pedersen Uffe Jakob Ortved Gang |
author_sort |
Christian Gluud |
title |
Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title_short |
Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title_full |
Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title_fullStr |
Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title_full_unstemmed |
Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title_sort |
lenient rate control versus strict rate control for atrial fibrillation: a protocol for the danish atrial fibrillation (danaf) randomised clinical trial |
publisher |
BMJ Publishing Group |
series |
BMJ Open |
issn |
2044-6055 |
publishDate |
2021-03-01 |
description |
Introduction Atrial fibrillation is the most common heart arrhythmia with a prevalence of approximately 2% in the western world. Atrial fibrillation is associated with an increased risk of death and morbidity. In many patients, a rate control strategy is recommended. The optimal heart rate target is disputed despite the results of the the RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient vs strict rate control II (RACE II) trial.Our primary objective will be to investigate the effect of lenient rate control strategy (<110 beats per minute (bpm) at rest) compared with strict rate control strategy (<80 bpm at rest) on quality of life in patients with persistent or permanent atrial fibrillation.Methods and analysis We plan a two-group, superiority randomised clinical trial. 350 outpatients with persistent or permanent atrial fibrillation will be recruited from four hospitals, across three regions in Denmark. Participants will be randomised 1:1 to a lenient medical rate control strategy (<110 bpm at rest) or a strict medical rate control strategy (<80 bpm at rest). The recruitment phase is planned to be 2 years with 3 years of follow-up. Recruitment is expected to start in January 2021. The primary outcome will be quality of life using the Short Form-36 (SF-36) questionnaire (physical component score). Secondary outcomes will be days alive outside hospital, symptom control using the Atrial Fibrillation Effect on Quality of Life, quality of life using the SF-36 questionnaire (mental component score) and serious adverse events. The primary assessment time point for all outcomes will be 1 year after randomisation.Ethics and dissemination Ethics approval was obtained through the ethics committee in Region Zealand. The design and findings will be published in peer-reviewed journals as well as be made available on ClinicalTrials.gov.Trial registration number NCT04542785. |
url |
https://bmjopen.bmj.com/content/11/3/e044744.full |
work_keys_str_mv |
AT christiangluud lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT emileiknielsen lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT joshuaburonfeinberg lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT michaelhechtolsen lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT axelbrandes lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT llanraymond lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT walterbjørnnielsen lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT frankstensgaardhansen lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT ulrikdixen lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT oledygpedersen lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT uffejakobortvedgang lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial |
_version_ |
1721329087409029120 |